Anli Jin

525 total citations
15 papers, 387 citations indexed

About

Anli Jin is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Anli Jin has authored 15 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Anli Jin's work include MicroRNA in disease regulation (5 papers), Immune cells in cancer (3 papers) and Circular RNAs in diseases (3 papers). Anli Jin is often cited by papers focused on MicroRNA in disease regulation (5 papers), Immune cells in cancer (3 papers) and Circular RNAs in diseases (3 papers). Anli Jin collaborates with scholars based in China, Ethiopia and India. Anli Jin's co-authors include Beili Wang, Xin‐Rong Yang, Hao Wang, Wenjing Yang, Jia Fan, Baishen Pan, Jian Zhou, Yun‐Fan Sun, Bo Hu and Yan Zhou and has published in prestigious journals such as Cell Death and Disease, Theranostics and Journal of Hematology & Oncology.

In The Last Decade

Anli Jin

15 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anli Jin China 10 211 115 90 86 81 15 387
Lin‐wen Wu China 12 225 1.1× 82 0.7× 88 1.0× 18 0.2× 35 0.4× 18 381
Jialin Feng China 12 310 1.5× 230 2.0× 55 0.6× 28 0.3× 32 0.4× 22 430
Lanya Li China 7 285 1.4× 79 0.7× 132 1.5× 13 0.2× 38 0.5× 12 433
Rui-Qing Peng China 10 222 1.1× 82 0.7× 239 2.7× 35 0.4× 150 1.9× 15 550
Tijana Tomić Serbia 5 255 1.2× 71 0.6× 102 1.1× 15 0.2× 34 0.4× 6 350
Elisa Ferrari Italy 7 268 1.3× 117 1.0× 89 1.0× 11 0.1× 82 1.0× 9 431
Chaoquan Hu China 10 284 1.3× 183 1.6× 111 1.2× 10 0.1× 29 0.4× 11 409
Xiangqiong Mo China 7 225 1.1× 121 1.1× 65 0.7× 12 0.1× 40 0.5× 7 362
Miao Xian China 10 191 0.9× 96 0.8× 104 1.2× 7 0.1× 127 1.6× 16 382

Countries citing papers authored by Anli Jin

Since Specialization
Citations

This map shows the geographic impact of Anli Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anli Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anli Jin more than expected).

Fields of papers citing papers by Anli Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anli Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anli Jin. The network helps show where Anli Jin may publish in the future.

Co-authorship network of co-authors of Anli Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Anli Jin. A scholar is included among the top collaborators of Anli Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anli Jin. Anli Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Jin, Anli, et al.. (2024). Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications. iScience. 27(9). 110637–110637. 2 indexed citations
3.
Jin, Anli, Yihui Yang, Xi Su, et al.. (2022). High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Journal of Clinical Laboratory Analysis. 36(3). e24259–e24259. 13 indexed citations
4.
Jin, Anli, Chunyan Zhang, Wenjing Zheng, et al.. (2022). CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clinical and Translational Medicine. 12(4). e794–e794. 26 indexed citations
5.
Liu, Te, Hao Wang, Anli Jin, et al.. (2022). Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10. Oxidative Medicine and Cellular Longevity. 2022(1). 6986445–6986445. 28 indexed citations
6.
Chen, Wei, Hao Wang, Tong Li, et al.. (2022). A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion. BMC Medical Genomics. 15(1). 34–34. 5 indexed citations
7.
Zhang, Chunyan, Wenjing Yang, Anli Jin, et al.. (2022). Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR‐34c‐5p/LGR4/β‐catenin axis activity. Journal of Cellular and Molecular Medicine. 26(8). 2218–2229. 12 indexed citations
8.
Yang, Wenjing, Beili Wang, Qian Yu, et al.. (2022). ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold. Theranostics. 12(14). 6189–6206. 11 indexed citations
9.
10.
Li, Tong, Te Liu, Wenjing Yang, et al.. (2022). Development of 14‐gene signature prognostic model based on metastasis for colorectal cancer. Journal of Clinical Laboratory Analysis. 37(1). e24800–e24800. 1 indexed citations
11.
Yang, Wenjing, Jiayi Yao, Hao Wang, et al.. (2021). The Diagnostic Value of Plasma Exosomal HSA_CIRC_0070396 for Hepatocellular Carcinoma. Biomarkers in Medicine. 15(5). 359–371. 41 indexed citations
12.
Yang, Wenjing, Yun‐Fan Sun, Anli Jin, et al.. (2020). BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death and Disease. 11(10). 895–895. 15 indexed citations
13.
14.
Yang, Wenjing, Chunyan Zhang, Yihao Li, et al.. (2019). Phosphorylase Kinase β Represents a Novel Prognostic Biomarker and Inhibits Malignant Phenotypes of Liver Cancer Cell. International Journal of Biological Sciences. 15(12). 2596–2606. 17 indexed citations
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lin‐wen Wu Breakdown of academic impact, for papers by Jialin Feng Breakdown of academic impact, for papers by Lanya Li Breakdown of academic impact, for papers by Rui-Qing Peng Breakdown of academic impact, for papers by Tijana Tomić Breakdown of academic impact, for papers by Elisa Ferrari Breakdown of academic impact, for papers by Chaoquan Hu Breakdown of academic impact, for papers by Xiangqiong Mo Breakdown of academic impact, for papers by Miao Xian
Rankless by CCL
2026